851916-41-1

Basic information

• Product Name: (R)-3-Methoxydihydro-2H-pyran-4(3H)-one
• Synonyms: (R)-3-Methoxydihydro-2H-pyran-4(3H)-one;(3R)-3-methoxyoxan-4-one
• CAS NO: 851916-41-1
• Molecular Formula: C6H10O3
• Molecular Weight: 130.1418
• Mol File: 851916-41-1.mol

Chemical Properties

• Boiling Point: 201.3±30.0 °C(Predicted)
• Appearance: /
• Density: 1.08±0.1 g/cm3(Predicted)
• CAS DataBase Reference: (R)-3-Methoxydihydro-2H-pyran-4(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-3-Methoxydihydro-2H-pyran-4(3H)-one(851916-41-1)
• EPA Substance Registry System: (R)-3-Methoxydihydro-2H-pyran-4(3H)-one(851916-41-1)

Safety Data

• Hazardous Substances Data: 851916-41-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
(R)-3-methoxydihydro-2H-pyran-4(3H)-one is used as a key intermediate in the synthesis of various pharmaceuticals for its versatile reactivity and unique structure, contributing to the development of new drugs with improved therapeutic properties.
Used in Flavor and Fragrance Industry:
(R)-3-methoxydihydro-2H-pyran-4(3H)-one is used as a flavoring agent or fragrance in various consumer products, such as food, beverages, and cosmetics, due to its pleasant aroma and taste.
Used in Antibacterial Applications:
(R)-3-methoxydihydro-2H-pyran-4(3H)-one is used as an antibacterial agent, exhibiting potential activity against various bacterial strains, making it a promising candidate for the development of new antimicrobial agents.
Used in Antifungal Applications:
(R)-3-methoxydihydro-2H-pyran-4(3H)-one is used as an antifungal agent, showing potential activity against different fungal species, which can be utilized in the development of antifungal drugs and treatments.
Overall, (R)-3-methoxydihydro-2H-pyran-4(3H)-one is a multifaceted chemical compound with a wide range of applications across various industries, including pharmaceuticals, flavor and fragrance, and antimicrobial agents, highlighting its significance in modern scientific and industrial applications.

Upstream product

• 851916-47-7 (R)-4,4-dimethoxytetrahydro-2H-pyran-3-ol 
• 77-78-1 dimethyl sulfate 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 104681-92-7 4,4-dimethoxytetrahydro-2H-pyran-3-ol 
• 693245-80-6 4,4-dimethoxy-5,6-dihydro-2H-pyran-3(4H)-one 

Downstream Products

• 1228112-41-1 1,5-anhydro-3-{[(1S,4R)-4-[(benzyloxy)carbonyl]-4-(1-hydroxycyclobutyl)cyclopent-2-en-1-yl]amino}-2,3-dideoxy-4-O-methyl-D-erythro-pentitol 
• 1461685-55-1 (2R,3aR,6aR)-benzyl 2-((3S,4S)-3-methoxytetrahydro-2H-pyran-4-ylamino)octahydropentalene-3a-carboxylate 
• 1461685-58-4 (2R,3aR,6aR)-benzyl 2-(2,2,2-trifluoro-N-((3S,4S)-3-methoxytetrahydro-2H-pyran-4-yl)acetamido)octahydropentalene-3a-carboxylate 

Relevant articles and documents

FUSED CYCLOPENTYL ANTAGONISTS OF CCR2

The present invention comprises compounds of Formula (I). wherein: R0, R1, R2, R3, R4, R5, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I)

CHEMOKINE RECEPTOR ANTAGONISTS

Disclosed herein are chemokine receptor antagonists of formula (I) wherein R1, R2, and R3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using

CHEMOKINE RECEPTOR ANTAGONISTS

Disclosed herein are chemokine receptor antagonists of formula (I) wherein R1, R2, and R3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using

AMINOCYCLOPENTYL PYRIDOPYRAZINONE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

Compounds of Formula I and Formula II (wherein A, E, j, k, m, n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R15, R16, R17, R18, R19, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, X, Y and Z are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.

PROCESS FOR THE PREPARATION OF CCR-2 ANTAGONIST

The present invention provides an efficient synthesis for the preparation of ((1R,3S)-3-isopropyl-3- {[3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl} cyclopentyl)[(3S,4S)-3-m ethoxytetrahydro- 2H-pyran-4-yl]amine and its succinate sal

CCR-2 ANTAGONIST SALT

The present invention provides an efficient synthesis for the preparation of ((1R,3S)-3-isopropyl-3-{[3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl}cyclopentyl)[(3S,4S)-3-m ethoxytetrahydro-2H-pyran-4-yl]amine and its succinate salt.